Long-term pharmacokinetic and pharmacological evaluations of a novel indole-benzazepinone derivative on obese Type 2 diabetes mellitus

Owing to the chronic nature of Type 2 diabetes mellitus, antidiabetic drugs must have long-lasting efficacy. Compound has a good inhibitory effect on acute hyperglycemia, but its long-term hypoglycemic effect has not been evaluated. Preliminary prediction and experimental pharmacokinetic results support the use of compound for long-term experiments. Long-term experiments demonstrated that compound significantly reduces blood glucose, improves the oral glucose tolerance of obese mice and has a positive effect on body weight, free fatty acid, hepatocyte steatosis and inflammatory cell infiltration. These findings lay a good foundation for the further exploration and development of novel glycogen phosphorylase inhibitors.